- Home
- LYEL vs OCGN Comparison
LYEL vs OCGN Comparison
Compare LYEL & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- OCGN
- Stock Information
- Founded
- LYEL 2018
- OCGN 2013
- Country
- LYEL United States
- OCGN United States
- Employees
- LYEL N/A
- OCGN N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYEL Health Care
- OCGN Health Care
- Exchange
- LYEL Nasdaq
- OCGN Nasdaq
- Market Cap
- LYEL 207.7M
- OCGN 189.6M
- IPO Year
- LYEL 2021
- OCGN N/A
- Fundamental
- Price
- LYEL $0.40
- OCGN $0.67
- Analyst Decision
- LYEL Sell
- OCGN Strong Buy
- Analyst Count
- LYEL 2
- OCGN 3
- Target Price
- LYEL $1.00
- OCGN $6.33
- AVG Volume (30 Days)
- LYEL 648.7K
- OCGN 3.2M
- Earning Date
- LYEL 05-20-2025
- OCGN 05-09-2025
- Dividend Yield
- LYEL N/A
- OCGN N/A
- EPS Growth
- LYEL N/A
- OCGN N/A
- EPS
- LYEL N/A
- OCGN N/A
- Revenue
- LYEL $61,000.00
- OCGN $4,522,000.00
- Revenue This Year
- LYEL N/A
- OCGN N/A
- Revenue Next Year
- LYEL N/A
- OCGN N/A
- P/E Ratio
- LYEL N/A
- OCGN N/A
- Revenue Growth
- LYEL N/A
- OCGN N/A
- 52 Week Low
- LYEL $0.39
- OCGN $0.52
- 52 Week High
- LYEL $2.88
- OCGN $2.06
- Technical
- Relative Strength Index (RSI)
- LYEL 37.66
- OCGN 46.49
- Support Level
- LYEL $0.41
- OCGN $0.65
- Resistance Level
- LYEL $0.51
- OCGN $0.75
- Average True Range (ATR)
- LYEL 0.05
- OCGN 0.05
- MACD
- LYEL 0.00
- OCGN -0.01
- Stochastic Oscillator
- LYEL 8.33
- OCGN 15.38
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").